A growing number of consumers are seeking alternatives to injectable GLP-1 medications, prompting Evolv to launch an oral supplement designed to mimic the effects of these drugs. The company’s flagship product, Evolv GLP-1, utilizes engineered yeast to deliver a molecule intended to activate both GLP-1 and GIP receptors, offering a non-invasive approach to weight management and metabolic health.
Prescriptions for GLP-1 drugs, originally developed to treat type 2 diabetes, have surged in recent years, increasing 587% between 2019 and 2024, as their weight loss potential became widely recognized. Yet, the reliance on injections presents a barrier for some potential users, fueling demand for alternative delivery methods.
Evolv’s approach differs fundamentally from traditional GLP-1 agonists. Instead of directly injecting synthetic peptides, the supplement aims to stimulate the body’s natural GLP-1 and GIP systems. The company asserts its product is the first oral supplement to deliver the “full power of GLP-1 naturally,” though clinical evidence supporting this claim remains limited.
As of February 6, 2026, Evolv has completed three studies and is currently conducting a 90-day trial involving 120 participants. Published data, however, is largely confined to company-run in vitro assays, animal safety studies, and user testimonials. The absence of peer-reviewed human studies demonstrating weight loss or metabolic benefits presents a challenge to evaluating the supplement’s efficacy.
The variability in user experiences with Evolv GLP-1 has also been noted. Some individuals report appetite suppression within days of starting the supplement, while others experience minimal changes after weeks of consistent apply. According to Evolv, this discrepancy is not attributable to the product itself, but rather to individual factors related to the broader GLP-1 landscape and realistic expectations regarding biomimetic approaches.
Becca McCarthy, a co-founder of Evolv, anticipated the growing interest in GLP-1 alternatives before the recent surge in demand for synthetic versions. The company is betting that a significant segment of consumers will prefer an orally available, “natural” option.
Experts caution that evaluating biomimetic GLP-1 supplements requires careful consideration of what GLP-1 actually does, how traditional agonists work, and what alternatives can realistically achieve. Native GLP-1 is naturally broken down by the DPP-4 enzyme within minutes, limiting its duration of effect. Whether Evolv’s approach can overcome this limitation and provide sustained appetite regulation remains to be seen.
Evolv’s fourth 90-day trial, involving 120 participants, is expected to conclude in May 2026, with results anticipated to be released shortly thereafter. The company has not yet announced plans for submitting the trial data for peer review.
